228. Bronchiolitis obliterans Clinical trials / Disease details
Clinical trials : 97 / Drugs : 118 - (DrugBank : 32) / Drug target genes : 33 - Drug target pathways : 156
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00624754 (ClinicalTrials.gov) | March 2008 | 15/2/2008 | Prospective Evaluation of the Efficacy of Budesonide/Formoterol in Bronchiolitis Obliterans in AHSCT | recipientsProspective Evaluation of the Efficacy of Budesonide/Formoterol (Symbicort®) in Bronchiolitis Obliterans in Allogeneic Haematopoietic Stem Cell Transplantation (AHSCT) Recipients | Obstructive Airway Disease | Drug: Formoterol/Budesonide;Drug: lactose | Assistance Publique - Hôpitaux de Paris | AstraZeneca | Completed | 16 Years | N/A | Both | 32 | Phase 2 | France |